Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection
AbstractClostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature >38°C), acute organ dysfunction, or serum white blood cell count >15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39%) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95% confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95%CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95%CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.
- Abstract views: 1255
- PDF: 467
- HTML: 314
Copyright (c) 2015 Dejan Micic, Krishna Rao, Bruno Caetano Trindade, Seth T. Walk, Elizabeth Chenoweth, Ruchika Jain, Itishree Trivedi, Kavitha Santhosh, Vincent B. Young, David M. Aronoff
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.